High levels of granzyme B expression in invasive cervical carcinoma correlates to poor response to treatment

Cancer Investigation

Volumn 26, Issue 5, 2008, Pages 499-503

  Guzman, Valeska B ^a,c   Silva, Ismael D C G ^a   Brenna, Sylvia M F ^b   Carvalho, Carmen R N ^a   Ribalta, Julisa C L ^a   Gerbase DeLima, Maria ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital and Maternity Leonor Mendes de Barros   (Brazil)

^c NONE   (Brazil)

Author keywords

Cervical cancer; Clinical outcome; Granzyme B; mRNA; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANZYME B; INDUCIBLE COSTIMULATOR LIGAND; INDUCIBLE COSTIMULATORY MOLECULE; PROTEIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 45949097594     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701805678     Document Type: Article

References (35)

1. Pisani, P.; Bray, F.; Parkin, D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002, 97, 72-81.
2. Villa, L.L. Human papillomaviruses and cervical cancer. Adv Cancer Res 1997, 71, 321-341.
3. zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2, 342-350.
4. Johnson, J.C.; Burnett, A.F.; Willet, G.D.; Young, M.A.; Doniger, J. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet Gynecol 1992, 79, 321-327.
5. Slavik, J.M.; Hutchcroft, J.E.; Bierer, B.E. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res 1999, 19, 1-24
6. Sharpe, A.H.; Freeman, G.J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2, 116-126.
7. Hodi, F.S.; Mihm, M.C.; Soiffer, R.J.; Haluska, F.G.; Butler, M.; Seiden, M.V.; Davis, T.; Henry-Spires, R.; MacRae, S.; Willman, A.; Padera, R.; Jaklitsch, M.T.; Shankar, S.; Chen, T.C.; Korman, A.; Allison, J.P.; Dranoff, G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003, 100, 4712-4717.
8. Kondo, M.C.; Ribalta, J.C.; da Silva, I.D.; Alves, M.T.; de Azevedo, Focchi, G.R.; Martins, N.V.; Focchi, J.; Granzyme, B. as a prognostic marker of cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 2005, 26, 87-89.
9. Bontkes, H.J.; de Gruijl, T.D.; Walboomers, J.M.; van den Muysenberg, A.J.; Gunther, A.W.; Scheper, R.J.; Meijer, C.J.; Kummer, J.A. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997, 76, 1353-1360.
10. Waggoner, S.E.; Cervical cancer. Lancet 2003, 361, 2217-2225.
11. National Comprehensive Cancer Network. Cervical Cancer. Clinical Practice Guidelines in Oncology 2006; version 1. Available in: http://www.nccn.org/ professionals/physician gls/f guidelines.asp#site
12. Pecorelli, S.; Odicino, F. Cervical cancer staging. Cancer J 2003, 9, 390-394.
13. Jain, D.; Srinivasan, R.; Patel, F.D.; Kumari, G.S.; Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003, 88, 22-28.
14. Ishikawa, H.; Sakurai, H.; Hasegawa, M.; Mitsuhashi, N.; Takahashi, M.; Masuda, N.; Nakajima, M.; Kitamoto, Y.; Saitoh, J.; Nakano, T. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004, 60, 513-521.
15. Trapani, J.A.; Smyth, M.J. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2, 735-747.
16. Shulzhenko, N.; Yambartsev, A.; Goncalves-Primo, A.; Gerbase-DeLima, M.; Morgun, A. Selection of control genes for quantitative RT-PCR based on microarray data. Biochem Biophys Res Commun 2005, 337, 306-312.
17. Ludwig, J.A.; Weinstein, J.N Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5, 845-856.
18. Dalton, W.S.; Friend, S.H. Cancer biomarkers-an invitation to the table. Science 2006, 312, 1165-1168.
19. Strand, C.; Enell, J.; Hedenfalk, I.; Fernö, M. RNA quality in frozen breast cancer samples and the influence on gene expression analysis: a comparison of three evaluation methods using microcapillary electrophoresis traces. Mol Biol 2007, 8, 38-47.
20. Auer, H.; Lyianarachchi, S.; Newsom, D.; Klisovic, M.I.; Marcucci, G.; Kornacker, K. Chipping away at the chip bias: RNA degradation in microarray analysis. Nat Genet 2003, 35, 292-293.
21. Skrypina, N.A.; Timofeeva, A.V.; Khaspekov, G.L; Savochkina, L.P.; Beabealashvilli RSh. TotalRNAsuitable for molecular biology analysis. J Biotechnol 2003, 105, 1-9.
22. Kondratiev, S.; Sabo, E.; Yakirevich, E.; Lavie, O.; Resnick, M.B. Intratumoral CD8+T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004, 10, 4450-4456.
23. ten Berge, R.L.; Dukers, D.F.; Oudejans, J.J.; Pulford, K.; Ossenkoppele, G.J.; de Jong, D.; Misere, J.F.; Meijer, C.J.; Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999, 93, 2688-2696.
24. Oudejans, J.J.; Jiwa, N.M.; Kummer, J.A.; Ossenkoppele, G.J.; van Heerde, P.; Baars, J.W.; Kluin, P.M.; Kluin-Nelemans, J.C.; van Diest, P.J.; Middeldorp, J.M.; Meijer, C.J. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997, 89, 1376-1382.
25. ten Berge, R.L.; Oudejans, J.J.; Dukers, D.F.; Meijer, J.W.; Ossenkoppele, G.J.; Meijer, C.J. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia 2001, 15, 458-464.
26. Oudejans, J.J.; Harijadi, H.; Kummer, J.A.; Tan, I.B.; Bloemena, E.; Middeldorp, J.M.; Bladergroen, B.; Dukers, D.F.; Vos, W.; Meijer, C.J.; High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol 2002, 198, 468-475.
27. Bird, P.I.; Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Immunol Cell Biol 1999, 77, 47-57.
28. Medema, J.P.; de Jong, J.; Peltenburg, L.T.; Verdegaal, E.M.; Gorter, A.; Bres, S.A; Franken, K.L; Hahne, M.; Albar, J.P.; Melief, C.J.; Offringa, R. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001, 98, 11515-11520.
29. Kemper, C.; Chan, A.C.; Green, J.M.; Brett, K.A.; Murphy, K.M.; Atkinson, J.P. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003, 421, 388-392.
30. Grossman, W.J.; Verbsky, J.W.; Tollefsen, B.L.; Kemper, C.; Atkinson, J.P.; Ley, T.J. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004, 104, 2840-2848.
31. Gondek, D.C.; Lu, L.F.; Quezada, S.A.; Sakaguchi, S.; Noelle, R.J.; Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005, 174, 1783-1786.
32. Cao, X.; Cai, S.F.; Fehniger, T.A.; Song, J.; Collins, L.I.; Piwnica-Worms, D.R.; Ley, T.J.; Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007, 27, 635-646.
33. Woo, E.Y., Chu, C.S.; Goletz, T.J.; Schlienger, K.; Yeh, H.; Coukos, G.; Rubin, S.C.; Kaiser, L.R.; June, C.H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61, 4766-4772.
34. Liyanage, U.K.; Moore, T.T.; Joo, H.G.; Tanaka, Y.; Herrmann, V.; Doherty, G.; Drebin, J.A.; Strasberg, S.M.; Eberlein, T.J.; Goedegebuure, P.S.; Linehan, D.C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169, 2756-2761.
35. Marshall, N.A.; Christie, L.E.; Munro, L.R.; Culligan, D.J.; Johnston, P.W.; Barker, R.N.; Vickers, M.A. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103, 1755-1762.